摘要
目的探究贝伐单抗联合吉非替尼治疗晚期表皮生长因子受体(EGFR)突变非小细胞肺癌(NSCLC)患者的临床疗效,并探讨其对血清尿酸(SUA)、C反应蛋白(CRP)表达、预后以及不良反应的影响。方法选取2015年12月-2016年12月秦皇岛市海港医院收治的68例晚期EGFR突变NSCLC患者作为本次研究对象,将其分为研究组和对照组,每组34例。对照组给予吉非替尼治疗,研究组给予贝伐单抗联合吉非替尼治疗。观察两组治疗后总有效率、SUA、CRP水平以及预后差异。结果研究组总有效率显著高于对照组(97.06%vs.70.59%)(χ^(2)=8.785,P<0.05)。治疗后,两组SUA水平均显著高于治疗前(t_(对照组)=4.065,t_(研究组)=6.593,P均<0.05),CRP水平显著低于治疗前(t_(对照组)=4.892,t_(研究组)=16.231,P均<0.05),且与对照组相比,研究组患者治疗后SUA水平显著升高(t=2.410,P<0.05),CRP水平显著降低(t=10.965,P<0.05)。研究组患者的死亡率显著低于对照组(2.94%vs.20.59%)(χ^(2)=5.100,P<0.05)。结论贝伐单抗联合吉非替尼可有效促进晚期EGFR突变NSCLC患者体内SUA水平的升高,CRP水平降低,从而达到抑制肿瘤细胞扩散,有效缓解患者病情以改善其预后的目的,值得在临床上推广应用。
Objective To investigate the clinical efficacy of bevacizumab combined with gefitinib in the treatment of advanced non-small cell lung cancer(NSCLC)with epidermal growth factor receptor(EGFR)mutation,and explore its effects on the expressions of serum uric acid(SUA),C-reactive protein(CRP),prognosis and adverse situation.Methods A total of 68 patients with advanced EGFR mutation NSCLC who were admitted to our hospital from December2015 to December 2016 were selected as the subjects of this study.They were divided into two groups.The 34 cases of NSCLC with late EGFR mutation in the control group were treated with gefitinib,while those in the study group were treated with bevacizumab and gefitinib.After treatment,the total effective rate,SUA,CRP levels and prognosis difference of the two groups were observed.Results The total effective rate of clinical treatment in the study group was significantly higher than that in the control group(97.06%vs.70.59%)(χ^(2)=8.785,P<0.05);after treatment,the SUA level of two groups was significantly higher than that before treatment(t_(control)=4.065,t_(study group)=6.593,P<0.05),and the CRP level was significantly lower than that before treatment(t_(control)=4.892,t_(study group)=16.231,P<0.05);compared with the control group,the SUA level of the study group was significantly higher(t=2.410,P<0.05),and the CRP level was significantly lower(t=10.965,P<0.05),and the mortality in the study group was significantly lower than that in the control group(2.94%vs.20.59%)(χ^(2)=5.100,P<0.05).Conclusion Bevacizumab combined with gefitinib might be through increasing SUA level and decreasing CRP level in NSCLC patients with late EGFR mutation to inhibit tumor cell proliferation,and hence effectively relieving patients’condition and improving their prognosis.
作者
董磊
刘春玲
尹燕鹰
DONG Lei;LIU Chun-ling;YIN Yan-ying(Department of Oncology,Haigang Hospital,Qinhuangdao,Hebei 066000,China)
出处
《热带医学杂志》
CAS
2021年第7期892-895,共4页
Journal of Tropical Medicine
基金
秦皇岛市科学技术研究与发展计划项目(201902A113)。
关键词
贝伐单抗
吉非替尼
表皮生长因子受体
非小细胞肺癌
Bevacizumab
Gefitinib
Epidermal growth factor receptor
Non-small cell lung cancer
